VIDEO: Real-world data show durability of Xipere in uveitic macular edema
Click Here to Manage Email Alerts
In this Healio Video Perspective from the Macula Society meeting, Michael A. Singer, MD, presents real-world data investigating Xipere for the treatment of uveitic macular edema.
According to Singer, ophthalmic treatments often underperform in real-world settings vs. clinical trials. In turn, Singer and colleagues looked at data from the IRIS Registry to assess Xipere (triamcinolone acetonide injectable suspension, Bausch + Lomb) in about 800 patients who were followed for 6 months.
The data showed that “patients who are given suprachoroidal triamcinolone seem to do better than the clinical trials indicate and that a vast majority of them can go 6 months or longer,” he said.
Collapse
Singer M. Durability and rescue therapy after suprachoroidal injection of triamcinolone acetonide injectable suspension for uveitic macular edema in clinical practice. Presented at: Macula Society meeting; Feb. 7-10, 2024; Palm Springs, California.
Read more about
Click Here to Manage Email Alerts